Cardiovascular Drugs and Therapy
IF
4.07
Papers
2857
Papers 3054
1 page of 306 pages (3,054 results)
Newest
#1Huan Chen (UTMB: University of Texas Medical Branch)H-Index: 3
#2Yochai Birnbaum (BCM: Baylor College of Medicine)H-Index: 56
Last. Yumei Ye (UTMB: University of Texas Medical Branch)H-Index: 28
view all 6 authors...
BACKGROUND SGLT2 inhibitors increase plasma ketone concentrations. It has been suggested that insulinopenia, along with an increase in the counter-regulatory hormones epinephrine, corticosterone, glucagon and growth hormone, can induce ketoacidosis, especially in type-1 diabetes (T1DM). Dehydration precipitates SGLT2 inhibitor-induced ketoacidosis in type-2 diabetes. We studied the effects of dapagliflozin and water deprivation on the development of ketoacidosis and the associated signaling path...
Source
#1Wenlin Xu (Fujian Medical University)
#2Meina Lv (Fujian Medical University)H-Index: 1
Last. Jinhua Zhang (Fujian Medical University)H-Index: 6
view all 10 authors...
PURPOSE We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke prevention and treatment in patients with atrial fibrillation (AF). METHODS A systematic search of four databases (PubMed, EMBASE, Web of Science, and Cochrane Library) was performed to identify randomized controlled trials (RCTs) reporting severe bleeding events in patients taking DOACs or vitamin K antagonists (VKAs). In this frequency-based network meta-analysis, odds ratios and 95% confidence intervals ...
Source
#1Amandine Gouverneur (University of Bordeaux)H-Index: 7
#2Paola Sanchez-PenaH-Index: 1
Last. Julien Bezin (University of Bordeaux)H-Index: 11
view all 6 authors...
PURPOSE PCSK9 might affect central nervous system development, neuronal apoptosis, and differentiation. We investigate the neurocognitive adverse events associated with the use of PCSK9 inhibitors (alirocumab and evolocumab) using pharmacovigilance reports. METHODS We used the World Health Organization pharmacovigilance database (VigiBase) to perform a disproportionality analysis comparing the proportion of neurocognitive adverse events reported with PCSK9 inhibitors versus the proportion of the...
Source
INTRODUCTION Recurrent event rates after myocardial infarction (MI) remain unacceptably high, in part because of the continued growth and destabilization of residual coronary atherosclerotic plaques, which may occur despite lipid-lowering therapy. Inflammation is an important contributor to this ongoing risk. Recent studies have shown that the broad-acting anti-inflammatory agent, colchicine, may reduce adverse cardiovascular events in patients post-MI, although the mechanistic basis for this re...
Source
#1Alexandra N. Nowbar (NIH: National Institutes of Health)H-Index: 11
#2Darrel P. Francis (NIH: National Institutes of Health)H-Index: 88
Last. Rasha Al-Lamee (NIH: National Institutes of Health)H-Index: 24
view all 3 authors...
The main aims of therapy in chronic stable angina are to reduce the risk of myocardial infarction and death and improve symptoms and quality of life (QoL). Unblinded trials have shown that revascularization does not reduce the risk of myocardial infarction or death but does appear to improve symptoms. However, symptoms are susceptible to the placebo effect which can bias therapies to appear more effective than they are. To assess the true physical impact of a treatment on symptoms, placebo-contr...
Source
#1Xiaolei Wang (SJTU: Shanghai Jiao Tong University)H-Index: 6
#2Zhe Sun (ShanghaiTech University)H-Index: 1
Last. Yi Li (SJTU: Shanghai Jiao Tong University)
view all 14 authors...
PURPOSE Macrophage apoptosis coupled with a defective phagocytic clearance of the apoptotic cells promotes plaque necrosis in advanced atherosclerosis, which causes acute atherothrombotic vascular disease. Nonsteroidal anti-inflammatory drug sulindac derivative K-80003 treatment was previously reported to dramatically attenuate atherosclerotic plaque progression and destabilization. However, the underlying mechanisms are not fully understood. This study aimed to determine the role of K-80003 on ...
Source
#1Yochai Birnbaum (BCM: Baylor College of Medicine)H-Index: 56
#2Regina Ye (University of Texas at Austin)
Last. Yumei Ye (UTMB: University of Texas Medical Branch)H-Index: 28
view all 3 authors...
BACKGROUND Ischemic postconditioning (PostC), repetitive cycles of re-occlusion, and reperfusion of the infarct-related artery immediately after reperfusion have been shown to limit myocardial infarct size in various animal models. Yet, translating the model into the clinical setting was disappointing, several clinical trials showing neutral effect. We hypothesized that aspirin loading could explain the differences between the pre-clinical and clinical studies. METHODS Male Sprague Dawley rats w...
Source
#1Skylar Buchan (The Texas Heart Institute)
#2Ronit Kar (The Texas Heart Institute)H-Index: 2
Last. Mehdi Razavi (The Texas Heart Institute)H-Index: 21
view all 5 authors...
Cardiac arrhythmias are a leading cause of morbidity and mortality in the developed world, estimated to be responsible for hundreds of thousands of deaths annually. Our understanding of the electrophysiological mechanisms of such arrhythmias has grown since they were formally characterized in the late nineteenth century, and this has led to the development of numerous devices and therapies that have markedly improved outcomes for patients affected by such conditions. Despite these advancements, ...
Source
#1Nikolaos P.E. Kadoglou (UCY: University of Cyprus)
#2Marianna Stasinopoulou (Academy of Athens)H-Index: 4
Statins, a class of lipid-lowering drugs, reduce morbidity and mortality in patients with established atherosclerosis-related cardiovascular disease. Early initiation of statin therapy after admission for acute coronary syndromes (ACS), stroke, or transient ischemic attack (TIA) is associated with improved cardiovascular outcomes. Moreover, high-dose statin treatment prior to coronary or carotid revascularization has been shown to reduce cardiovascular events in these patients. However, many pat...
Source
#1Felix Hofer (Medical University of Vienna)H-Index: 2
#2N Kazem (Medical University of Vienna)H-Index: 2
Last. Alexander Niessner (Medical University of Vienna)H-Index: 32
view all 10 authors...
PURPOSE The benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) has been unequivocally proven in randomized, controlled trials. However, real-world evidence assessing the implementation of SGLT2i in clinical practice and their benefit in HF outside of highly selected study populations is limited. METHODS Patients with HF and T2DM admitted to the cardiology ward of the Medical ...
Source
12345678910
Top fields of study
Endocrinology
Cardiology
Heart failure
Anesthesia
Myocardial infarction
Diabetes mellitus
Medicine